Pregnancy and Neonatal Outcomes in COVID-19
Pregnancy and Neonatal Outcomes in COVID-19: A global registry of women with suspected or confirmed SARS-CoV-2 infeciton in pregnancy and their neonates, understanding natural history to guide treatment and prevention
Sponsor: Imperial College of Science, Technology and Medicine
CI: Edward Mullins
Approval Date: 18 April 2020
To better understand some specific research questions as to how COVID-19 affects early pregnancy, fetal growth, prematurity and virus transmission to the baby the researchers will construct a registry of women with suspected and confirmed COVID-19 from early pregnancy to after delivery of the baby. Healthcare professionals from the UK and across many international centres will contribute data via a web portal.
The current coronavirus outbreak (COVID-19) is likely to affect hundreds of pregnant women globally. Middle Eastern Respiratory Syndrome (MERS) and Severe Acute Respiratoy Syndrome (SARS), also coronaviruses, caused more severe illness - particularly lung infections- in pregnant vs. non-pregnant women. There has been a report of nine women affected by COVID-19 in the latter third of their pregnancy, many more are likely to be affected. There is a data-gap on the effect of SARs-CoV-2 infection and COVID-19 at other stages of pregnancy e.g. early pregnancy and its effect on the unborn and newborn baby. Maternity services and individual maternity centres are currently developing their responses using national and WHO guidance for non-pregnant women. PAN-COVID will develop a global database detailing a number of outcomes (death of the baby or mother, stillbirth, miscarriage, pregnancy complications, gestational age at delivery, delivery method and testing the baby for SARS-CoV-2). The aim of this database is to understand the natural history of SARS-CoV-2 and COVID-19 and the impact on mothers and their babies to guide both treatment and prevention.Back to listing